Reflex Ready: Setting the New Standard for Cholangiocarcinoma Care at Royal North Shore Hospital, NSW

A comprehensive overview of the rationale, methodology, and clinical outcomes behind the Royal North Shore Hospital MDT’s transition to routine reflex molecular testing for cholangiocarcinoma

The role of ivosidenib in patients with locally advanced or metastatic mIDH1 cholangiocarcinoma – presented by Associate Professor Matthew Burge

Associate Professor Matthew Burge MB ChB, FRACP

Oncology Watch 19 - Genomics, early onset cancers, survivorship

Professor David Thomas Director, Centre for Molecular Oncology, UNSW, Chief of Science and Strategy, Omico

Oncology Watch 18 - Rare cancers and tumor agnostic therapies

Professor David Thomas

Director, Centre for Molecular Oncology, UNSW, Chief of Science and Strategy, Omico

Oncology Watch 16 - Precision medicine and how it can impact the outcomes for rare cancer patients

Professor David Thomas Director, Centre for Molecular Oncology, UNSW

Chief of Science and Strategy, Omico

Oncology Watch 17 - CheckMate 274: Adjuvant nivolumab in high-risk UC

Professor Niall Corcoran MB BCh BAO PhD FRACS(Urol)

ANZCHOG Highlights 2024

Dr Matthew O'Connor MBBS, FRACP, Paediatric Oncologist Women’s and Children’s Hospital, Adelaide, Senior Clinical Lecturer University of Adelaide

Oncology Watch 15 - Acute kidney injury in patients with cancer

Professor Gopi Rangan FRACP, MB BS, PhD, MGenomics, MBA

Oncology Watch 14 - Clinical approach to tumour lysis syndrome

Professor Gopi Rangan FRACP, MB BS, PhD, MGenomics, MBA

Oncology Watch 13 - New options to target ROS1 fusions in NSCLC

Professor Ben Solomon MBBS, PhD, FRACP

Oncology Watch 12 - Enfortumab Vedotin: Quality of life outcomes from EV-301

Associate Professor Andrew Weickhardt MBBS(Hons) FRACP DMedSc

Oncology Watch 11 - MARS2 Study

Associate Professor Thomas John

Oncology Watch 10 - FGFR inhibitors in urothelial cancer

Associate Professor Andrew Weickhardt MBBS(Hons) FRACP DMedSc

Oncology Watch 9 - 1st line Treatment of Metastatic Urothelial Cancer

Associate Professor Andrew Weickhardt MBBS(Hons) FRACP DMedSc

Oncology Watch 8 - Antibody Drug Conjugates for Urothelial Cancer

Associate Professor Andrew Weickhardt MBBS(Hons) FRACP DMedSc

Oncology Watch 7 - MRI for T-staging in Bladder Cancer

Associate Professor Niall Corcoran MB BCh BAO PhD FRACS (Urol)

Oncology Watch 6 - Molecular Classification of Muscle Invasive Bladder Cancer: What is it and why do it?

Associate Professor Niall Corcoran MB BCh BAO PhD FRACS(Urol)

Oncology Watch 5 - Immune checkpoint inhibition as adjuvant therapy post radical surgery for high-risk urothelial cancer

Associate Professor Niall Corcoran MB BCh BAO PhD FRACS(Urol)

Uptake of bone modifying agent in patients with HER2+ mBC with bone metastases in the real-world (TABITHA, Australia)

Dr. Vanessa Wong BMedSc MBBS (Hons) FRACP

Oncology Watch 4 - Sun Smart Behaviour

Professor Michael Henderson MBBS BMedSc MD FRACS

Oncology Watch 2- What’s new in Radiotherapy for cSCC

Professor Gerald Fogarty BSc MBBS PhD FRANZCR (FRO)

Oncology Watch 1 - cSCC

Professor Michael Henderson MBBS BMedSc MD FRACS

The changing role of radical prostatectomy

Prof James Eastham & A/Prof Declan Murphy

PSMA PET scanning in prostate cancer

Prof Bertrand Tombal & A/Prof Declan Murphy

Reflex Ready: Setting the New Standard for Cholangiocarcinoma Care at Royal North Shore Hospital, NSW

The role of ivosidenib in patients with locally advanced or metastatic mIDH1 cholangiocarcinoma – presented by Associate Professor Matthew Burge

Oncology Watch 19 - Genomics, early onset cancers, survivorship

Oncology Watch 18 - Rare cancers and tumor agnostic therapies

Oncology Watch 16 - Precision medicine and how it can impact the outcomes for rare cancer patients

Oncology Watch 17 - CheckMate 274: Adjuvant nivolumab in high-risk UC

ANZCHOG Highlights 2024

Oncology Watch 15 - Acute kidney injury in patients with cancer

Oncology Watch 14 - Clinical approach to tumour lysis syndrome

Oncology Watch 13 - New options to target ROS1 fusions in NSCLC

Oncology Watch 12 - Enfortumab Vedotin: Quality of life outcomes from EV-301

Oncology Watch 11 - MARS2 Study

Oncology Watch 10 - FGFR inhibitors in urothelial cancer

Oncology Watch 9 - 1st line Treatment of Metastatic Urothelial Cancer

Oncology Watch 8 - Antibody Drug Conjugates for Urothelial Cancer

Oncology Watch 7 - MRI for T-staging in Bladder Cancer

Oncology Watch 6 - Molecular Classification of Muscle Invasive Bladder Cancer: What is it and why do it?

Oncology Watch 5 - Immune checkpoint inhibition as adjuvant therapy post radical surgery for high-risk urothelial cancer

Uptake of bone modifying agent in patients with HER2+ mBC with bone metastases in the real-world (TABITHA, Australia)

Oncology Watch 4 - Sun Smart Behaviour

Oncology Watch 2- What’s new in Radiotherapy for cSCC

Oncology Watch 1 - cSCC

The changing role of radical prostatectomy

PSMA PET scanning in prostate cancer

Get Free publications straight to your inbox.